{"filing":{"accession_number":"0001193125-26-331596","cik":"0001921865","ticker":"ASPI","company_name":"ASP Isotopes Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"aspi-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1921865/000119312526331596/aspi-20260804.htm"},"events":[{"id":23874,"run_id":21591,"accession_number":"0001193125-26-331596","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"ASP Isotopes disclosed a shareholder letter dated August 4, 2026, providing detailed operational and financial updates across multiple business divisions (PET Labs, Renergen, stable isotopes, QLE, Alpa Theranostics) in advance of the company's announcement of Q2 2026 financial results, including revenue guidance and EBITDA targets.","company_name":"ASP Isotopes Inc.","ticker":"ASPI","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24225,"accession_number":"0001193125-26-331596","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses Item 2.02 (Results of Operations and Financial Condition) and references a shareholder letter issued on August 4, 2026, \"as we prepare to announce financial results for the second quarter of 2026.\" The letter provides detailed operational and financial updates across multiple business divisions (PET Labs, Renergen, stable isotopes, QLE, Alpa Theranostics), including revenue guidance, EBITDA targets, and production milestones. While the actual Q2 2026 financial results are not yet released, this is a material pre-earnings disclosure of operational performance and forward guidance that would affect investor assessment of the company's financial condition and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:24:11.472171+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24226,"accession_number":"0001193125-26-331596","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"This Item 7.01 disclosure incorporates a shareholder letter from the CEO that updates on multiple business developments: PET Labs revenue growth (50% organic growth, $14M FY2026 forecast), Renergen helium production commencement (expected pre-Sept 30, 2026, $27M annualized revenues), stable isotope facility progress, planned reverse merger of Renergen with ENDRA, QLE public listing pursuit, and Alpa Theranostics clinical advancement. While the letter addresses material operational and strategic developments across multiple divisions and includes forward-looking guidance on revenues and EBITDA targets, it does not fit neatly into a single defined event category—it is a comprehensive business update spanning operational progress, subsidiary transactions, and strategic positioning rather than a discrete event like M\u0026A completion, earnings release, or executive change. The domain is clearly material and financial/operational, but the event itself is a multi-faceted strategic update best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:24:11.472171+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24225,"accession_number":"0001193125-26-331596","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses Item 2.02 (Results of Operations and Financial Condition) and references a shareholder letter issued on August 4, 2026, \"as we prepare to announce financial results for the second quarter of 2026.\" The letter provides detailed operational and financial updates across multiple business divisions (PET Labs, Renergen, stable isotopes, QLE, Alpa Theranostics), including revenue guidance, EBITDA targets, and production milestones. While the actual Q2 2026 financial results are not yet released, this is a material pre-earnings disclosure of operational performance and forward guidance that would affect investor assessment of the company's financial condition and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:24:11.472171+00:00","company_name":"ASP Isotopes Inc.","ticker":"ASPI","filing_date":"2026-08-04"},{"id":24226,"accession_number":"0001193125-26-331596","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"This Item 7.01 disclosure incorporates a shareholder letter from the CEO that updates on multiple business developments: PET Labs revenue growth (50% organic growth, $14M FY2026 forecast), Renergen helium production commencement (expected pre-Sept 30, 2026, $27M annualized revenues), stable isotope facility progress, planned reverse merger of Renergen with ENDRA, QLE public listing pursuit, and Alpa Theranostics clinical advancement. While the letter addresses material operational and strategic developments across multiple divisions and includes forward-looking guidance on revenues and EBITDA targets, it does not fit neatly into a single defined event category—it is a comprehensive business update spanning operational progress, subsidiary transactions, and strategic positioning rather than a discrete event like M\u0026A completion, earnings release, or executive change. The domain is clearly material and financial/operational, but the event itself is a multi-faceted strategic update best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:24:11.472171+00:00","company_name":"ASP Isotopes Inc.","ticker":"ASPI","filing_date":"2026-08-04"}]}